Navigation Links
New Recombinant XYNTHA Now Available for Patients with Hemophilia A
Date:9/8/2008

out XYNTHA.

Wyeth Hemophilia Patient Access Programs

Wyeth works to help patients with hemophilia have ongoing access to their hemophilia therapies. Through its Factor Resource Program, Wyeth provides several services to assist patients experiencing financial hardship or treatment access issues, including the Insurance-Coverage Program, the Patient Assistance Program, and the Wyeth Hemophilia Hotline (1-888-999-2349).

About Hemophilia A

Hemophilia A is a rare, inherited blood-clotting disorder characterized by spontaneous hemorrhages or prolonged bleeding, typically into joints and soft tissue. People with hemophilia A are deficient in a key protein -- factor VIII -- that is vital in the clotting mechanism to prevent bleeding. Most patients with hemophilia A are dependent on factor VIII replacement therapy.

Indication for XYNTHA

XYNTHA Antihemophilic Factor (Recombinant), Plasma/Albumin-Free is indicated for the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A. XYNTHA does not contain von Willebrand factor and, therefore, is not indicated in Von Willebrand's disease.

Important Safety Information for XYNTHA

-- Anaphylaxis and severe hypersensitivity reactions are possible. Patients should be informed of the early signs of hypersensitivity reactions [including hives (rash with itching), generalized urticaria, tightness of the chest, wheezing, hypotension] and anaphylaxis. Patients should be advised to discontinue use of the product and contact their physician if these symptoms occur.

-- Patients should be advised to contact their physician or treatment facility for further treatment and/or assessment if they experience a lack of a clinical response to factor VIII replacement therapy, as this may be a manifestation of an inhibitor.

-- The most common adverse re
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm
2. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
3. Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies
4. STALLERGENES and Protein eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Recombinant Human Renin - Crystallographic Grade
7. Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich
8. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
9. Mymetics Corporation Information to be Available Through Standard & Poors Market Access Program
10. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
11. Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Merck KGaA, Darmstadt, ... and top-quality high-tech products in the healthcare, life science ... US-based company Nano-C, their development and launch of promising ... photovoltaics (OPV). Merck KGaA, Darmstadt, Germany ... growing OPV sector. Novel derivatives: highly stable, ...
(Date:8/3/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... life-threatening diseases, today announced that it will host its ... on Thursday, August 13, 2015 at 4:30 p.m. Eastern ... the release of fiscal 2016 first quarter results.  A ... two hours after the call at the Investor Relations ...
(Date:8/3/2015)... GERMANTOWN, Md. , Aug. 3, 2015   ... it will release first half and second quarter 2015 ... 10 th , 2015.  The Company will host a ... results and provide a general business update. ... (Domestic US) and 1-412-902-4262 (International), and asking to join ...
(Date:8/3/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a ... autologous cell therapies, announced today that RepliCel,s CEO, David ... in Minneapolis, Minnesota on August 5 ... highlight RepliCel,s 18-month milestones including CE Mark for its RCI-02 ... clinical data from both RCT-01 (tendon) and RCS-01 (skin) clinical ...
Breaking Biology Technology:Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2
... 19, 2012  Nautilus Neurosciences announced today that their ... subsidiary of Stellar Pharmaceuticals, was granted a Notice ... CAMBIA® (diclofenac potassium for oral solution) in the ... in adults. CAMBIA® is expected to be launched ...
... Cancer Research Centre (CNIO) routinely runs such tests on samples ... just the first step towards a truly personalised medicine. And ... in each organism at a molecular scale: the genes that ... antibodies circulating through the bloodstream; and the length of the ...
... of yoghurt have a note telling you that the product ... the spatial arrangement of their atoms. The two"isomers", L(+) and ... light to the right or left respectively. Of course the ... is not confined to solutions of yoghurt. Light interacts in ...
Cached Biology Technology:Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine 2Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine 3CNIO researchers take part in the most comprehensive personalized medicine study performed to date 2CNIO researchers take part in the most comprehensive personalized medicine study performed to date 3Designer lights from the physics lab 2
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/8/2015)... YORK , July 8, 2015  BD (Becton, ... BD & Guidepoint Mentor, a new program ... Guidepoint,s expert network services. BD is ... to improve healthcare delivery and outcomes and, with the ... entrepreneur will be able to directly engage with industry ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... malaria parasites form mutations that make them stubbornly resistant ... new treatments for a disease that afflicts more than ... disease models using yeast and successfully introduced five mutations ... The study, featured as the cover story of the ...
... consequences for humans and most animals but not Australia's ... The University of Queensland has found that unlike most ... starvation, the green-striped burrowing frog is able to absorb ... food, than frogs that had eaten regularly. , "They ...
... community over the evolution of the Great White shark, and ... Wright State University Lake Campus, is right in the middle ... one of the most feared predators of the sea, evolved ... rests with the mako shark. , "Most scientists would probably ...
Cached Biology News:Molecular models advance the fight against malaria 2A frog's life is food for thought 2A frog's life is food for thought 3Great White shark evolution debate involves WSU Lake Campus geology professor 2
Agarose, Biotechnology grade, 500g...
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
... The c-Jun proto-oncogene was first identified as ... v-jun oncogene. Jun B and Jun D have ... in their C-terminal regions, which are involved in ... which are involved in transcriptional activation, diverge. ...
...
Biology Products: